Skip to main content
Article
Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire
Quantitative Health Sciences Publications and Presentations
  • Jean Bousquet, Hopital Arnaud de Villeneuve
  • J. Duchateau, Hopital Universitaire Saint-Pierre
  • J. C. Pignat, Hopital de la Croix-Rousse
  • C. Fayol, MAPI
  • P. Marquis, MAPI
  • S. Mariz, UCB Pharma Ltd.
  • John E. Ware, Jr., University of Massachusetts Medical School
  • B. Valentin, UCB S.A. Pharmaceutical Sector
  • B. Burtin, UCB S.A. Pharmaceutical Sector
UMMS Affiliation
Department of Quantitative Health Sciences
Date
8-1-1996
Document Type
Article
Medical Subject Headings
Adolescent; Adult; Belgium; Cetirizine; Double-Blind Method; Follow-Up Studies; France; *Health Surveys; Humans; Middle Aged; Patient Compliance; *Quality of Life; *Questionnaires; Rhinitis, Allergic, Perennial; Treatment Outcome
Abstract

BACKGROUND AND AIM: Perennial allergic rhinitis impairs social life, but it is not known whether quality of life may be improved when patients are treated with an H1-blocker. A randomized, double-blind, placebo-controlled study was carried out with cetirizine to assess the effect of this drug on quality of life.

METHODS: Two hundred seventy-four patients with perennial allergic rhinitis were tested. Quality of life was measured by using the Medical Outcome Study Short-Form Health Survey (SF-36) questionnaire. After a 2-week run-in period, cetirizine, 10 mg once daily, (136 patients) or placebo (138 patients) was given for the next 6 weeks. The SF-36 questionnaire was administered after the run-in period (at the start of treatment) and after 1 and 6 weeks of treatment. Symptom-medication scores were measured daily during the study.

RESULTS: After the run-in period (baseline), there were no significant differences between the cetirizine and placebo groups in terms of symptoms or quality-of-life scores. After 6 weeks of treatment, percentage of days without rhinitis or with only mild rhinitis symptoms was significantly greater in the cetirizine group in comparison with the placebo group (p < 0.0001, Mann-Whitney U test). All of the nine quality-of-life dimensions were significantly improved (from p = 0.01 to p < 0.0001, Mann-Whitney U test) after 1 and 6 weeks of cetirizine treatment compared with placebo. There was no improvement in the placebo group.

CONCLUSIONS: This study is the first to demonstrate that an H1-blocker, cetirizine, can improve quality of life for patients with perennial allergic rhinitis.

Rights and Permissions
Citation: J Allergy Clin Immunol. 1996 Aug;98(2):309-16. Link to article on publisher's site
Related Resources
Link to Article in PubMed
Citation Information
Jean Bousquet, J. Duchateau, J. C. Pignat, C. Fayol, et al.. "Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire" Vol. 98 Iss. 2 (1996) ISSN: 0091-6749 (Linking)
Available at: http://works.bepress.com/john_ware/98/